Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 12;11(12):e007785. doi: 10.1136/jitc-2023-007785

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

XTX101+anti-PD-1 combination therapy in MC38 tumor model. In vivo study was performed to evaluate the therapeutic TGI of XTX101 in combination with an anti-muPD-1 antibody RMP1-14 in B-hCTLA-4 mice bearing syngeneic MC38 murine colon carcinoma tumors (n=8 per group). Isotype control mAb and XTX101 were given to animals as a single intravenous injection on day 0, whereas anti-murine PD-1 mAb was given every 3 days (Q3D) three times by intraperitoneal injection starting on day 0. (A) Tumor volume was measured twice weekly and plotted as mean±SEM. (B) Body weight % change plotted as mean±SEM from day 0 body weight. A two-way analysis of variance with Dunnett’s multiple comparisons post-test was performed (*p<0.05; **p<0.01; ***p<0.001; n.s.=not significant). mAb, monoclonal antibody; TGI, tumor growth inhibition.